Keryx Biopharmaceuticals (NASDAQ: KERX) posted its quarterly earnings results on Tuesday. The company reported ($0.09) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.08) by $0.01. During the same quarter in the prior year, the company posted ($0.12) earnings per share.

Several analysts have also recently commented on the stock. Analysts at Oppenheimer raised their price target on shares of Keryx Biopharmaceuticals to $11.00 in a research note to investors on Tuesday, January 29th. On the ratings front, analysts at Ladenburg Thalmann raised their price target on shares of Keryx Biopharmaceuticals from $5.00 to $15.00 in a research note to investors on Tuesday, January 29th. They now have a “buy” rating on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of Keryx Biopharmaceuticals from $4.00 to $13.00 in a research note to investors on Tuesday, January 29th. They now have a “buy” rating on the stock.

Keryx Biopharmaceuticals (KERX) opened at 7.35 on Tuesday. Keryx Biopharmaceuticals (KERX) has a 1-year low of $1.28 and a 1-year high of $9.98. The stock’s 50-day moving average is currently $6.62. The company’s market cap is $528.6 million.

Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.